Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection

N Nicholas G. Herbert (Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford) G Gabriela Cromhout (Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal) N Nomonde Bengu (Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal) R Rowena Fillis (Harry Gwala Regional Hospital) S Samantha Kannie (General Justice Gizenga Mpanza Regional Hospital) J Jeroen van Lobenstein (General Justice Gizenga Mpanza Regional Hospital) K Kogielambal Chinniah (Mahatma Gandhi Memorial Hospital) C Constant Kapongo (Queen Nandi Regional Hospital) R Roopesh Bhoola (Harry Gwala Regional Hospital) M Malini Krishna (General Justice Gizenga Mpanza Regional Hospital) N Noxolo Mchunu (Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal) T Thilona Arumugam (School of Laboratory Medicine and Medical Sciences College of Health Sciences, University of KwaZulu-Natal) K Krista Dong (Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University) S Sunetra Gupta (Department of Biology, University of Oxford OX1 3SY) C Christian Brander (Irsicaixa-Acquired Immunodeficiency Syndrome, Research Institute) M Mary Carrington T Thumbi Ndung’u (Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal) V Veron Ramsuran (School of Laboratory Medicine and Medical Sciences College of Health Sciences, University of KwaZulu-Natal) B Bridget S. Penman (Department of Biology, Life and Mind Building, University of Oxford) P Philip J. R. Goulder (Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford)

Abstract

MHC polymorphism is explained by natural selection driven by the MHC-dependent impact of certain infections, inflammatory conditions, autoimmune diseases, and cancers. However, examples of human disease driving this process are rare. We evaluated the impact of HIV-1 in altering HLA-I frequencies in KwaZulu-Natal, South Africa, and the influence of antiretroviral therapy (ART) on this process. In a historical mother-child cohort in the pre-ART era (1998–2005), HIV-1 survival and vertical transmission were both strongly HLA-B dependent: “disease-susceptible” HLA-B alleles (HLA-B*18/B*45:01/B*58:02) increased adult AIDS progression and vertical transmission (OR 1.6, P = 0.01), whereas “protective” HLA-B alleles (HLA-B*57/B*58:01/B*81:01) slowed AIDS progression, and decreased vertical transmission (OR 0.57, P = 0.002). By contrast, in contemporary antenatal KwaZulu-Natal cohorts in the ART era (2015–2025) the impact of HLA-B on HIV-1 disease outcome and vertical transmission is dramatically reduced. Using these and reported data, we constructed a model to estimate the impact of HIV-1 on HLA-B frequencies in KwaZulu-Natal, both in the prevailing setting of ART and in a hypothetical counterfactual scenario where ART was never rolled out. Over the 45-y period 1990–2035, in the absence of ART, the proportion of the population possessing any “protective” HLA-B allele was projected to increase from 23 to 42% (allele frequencies increasing from 0.12 to 0.24), and the proportion of the population possessing any “disease-susceptible” HLA-B allele was projected to decrease from 28 to 18% (allele frequencies declining from 0.15 to 0.092). The introduction of ART radically slows HLA-B frequency change. These data therefore demonstrate the potential for natural selection from an infectious disease to alter human population genetics within decades, and for the successful roll-out of therapy to halt this process.

Article Details

Volume / Issue Vol. 123, Issue 19
Published May 12, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (20)

N

Nicholas G. Herbert

Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford

G

Gabriela Cromhout

Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal

N

Nomonde Bengu

Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal

R

Rowena Fillis

Harry Gwala Regional Hospital

S

Samantha Kannie

General Justice Gizenga Mpanza Regional Hospital

J

Jeroen van Lobenstein

General Justice Gizenga Mpanza Regional Hospital

K

Kogielambal Chinniah

Mahatma Gandhi Memorial Hospital

C

Constant Kapongo

Queen Nandi Regional Hospital

R

Roopesh Bhoola

Harry Gwala Regional Hospital

M

Malini Krishna

General Justice Gizenga Mpanza Regional Hospital

N

Noxolo Mchunu

Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal

T

Thilona Arumugam

School of Laboratory Medicine and Medical Sciences College of Health Sciences, University of KwaZulu-Natal

K

Krista Dong

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University

S

Sunetra Gupta

Department of Biology, University of Oxford OX1 3SY

C

Christian Brander

Irsicaixa-Acquired Immunodeficiency Syndrome, Research Institute

M

Mary Carrington

T

Thumbi Ndung’u

Human Immunodeficiency Virus, Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal

V

Veron Ramsuran

School of Laboratory Medicine and Medical Sciences College of Health Sciences, University of KwaZulu-Natal

B

Bridget S. Penman

Department of Biology, Life and Mind Building, University of Oxford

P

Philip J. R. Goulder

Peter Medawar Building for Pathogen Research, Department of Paediatrics, University of Oxford